• Daily dose of fosfomycin is determined based on the indication, severity and site of the infection, suspectibility of the pathogens to fosfomycin and the renal function.
• Duration of the treatment should depend on the type of infection, the severity of the infection and the patient's clinical response.
• The duration of IV infusion should be atleast 30 minutes for the 4g fosfomycin injection.
• In hepatic impairment patients there is no dose adjustment required.
• No dose adjustment is recommended in patients within estimated creatinine clearance between 40-80 ml/min. However, caution should be exercised in these cases, particularly if doses at the higher end of the recommended range are considered.
• In patients with impaired renal function the dose of fosfomycin must be adjusted to the degree of renal impairment.

An important therapeutic solution for MDR-GNB* infections

Fosfomycin Potentially Adds a Significant New Intravenous Treatment to the Antibiotic Armamentarium

• Fosfomycin exerts bactericidal activity against a broad range of gram-negative and gram- positive pathogens, including extended-spectrum beta-lactamase- and carbapenemase- producing bacteria.¹
• Fosfomycin also has good bone dissemination, and numerous in vitro studies have demonstra- ted its activity against biofilms.
• Fosfomycin has significant synergistic activity with daptomycin, rifampicin, vancomycin, linezolid and fusidic acid against biofilms of gram-positive pathogens, as well synergistic activity with colistin with ciprofloxacin against gram-negative pathogens.
• Fosfomycin relatively safe and tolerable adverse effect profile make it a great addition to waning antibiotic armamentarium.³
• Fosfomycin contains a three-membered epoxide ring with a direct carbon to phosphorous bond that bypasses the intermediate oxygen bond commonly present in other organophosphorous compounds; this structure makes the agent unique from other antibiotics.³
• Intravenous (IV) fosfomycin is an interesting choice for the treatment of central nervous system infections as it is safe, efficient and possesses the necessary pharmacokinetics/pharmacodyna- mics and antibacterial range.
• For patients with severe gram-negative infections, fosfomycin offers a new IV therapeutic option with a differentiated mechanism of action. It was successful in treating complicated urinary tract infections, including complicated urinary tract infection.